An update on disordered iron metabolism and iron overload

References

• Fleming MD. The regulation of hepcidin and its effects on systemic and cellular iron metabolism. Hematology Am Soc Hematol Educ Program 2008; 2008: 151–158.
   Google Scholar
• Hershko C Link G, Cabantchik I. Pathophysiology of iron overload. Ann NY Acad Sci 1998; 850: 191–201.
   PubMed Web of Science ®Google Scholar
• Ganz T. Hepcidin and its role in regulating systemic iron metabolism. Hematology Am Soc Hematol Educ Program 2006; 2006: 29–35.
   Google Scholar
• Tanno T, Bhanu NV, Oneal PA et al. Identification of TWSG1 as asecond novel erythroid regulator of hepcidin expression in murine and human cells. Blood 2009; 114: 181–186.
   PubMed Web of Science ®Google Scholar
• Origa R, Galanello R, Ganz T et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica 2007; 92: 583–588.
   PubMed Web of Science ®Google Scholar
• Kell DB. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics 2009; 2: 2.
   PubMed Web of Science ®Google Scholar
• Walter PB, Harmatzl PR, Higa A et al. Iron overload diminishesthe effectiveness of the innate immune response in thalassemia major: a possible mechanism for increased infection risk. ASH Annu Meet Abstr 2009; 114: 4071.
   Google Scholar
• Melchiori L, Gardenghi S, Guy EC et al. Use of Jak2 inhibitors tolimit ineffective erythropoiesis and iron absorption in mice affected by beta-thalassemia and other disorders of red cell production. ASH Annu Meet Abstr 2009; 114: 2020.
   Google Scholar
• Gardenghi S, Marongiu MF, Ramos P et al. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood 2007; 109: 5027–5035.
   PubMed Web of Science ®Google Scholar
• Melis MA, Cau M, Congiu R et al. A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. Haematologica 2008; 93: 1473–1479.
   PubMed Web of Science ®Google Scholar
• Ramsay AJ, Dong Y, Hunt ML et al. Matriptase-2 (TMPRSS6): a proteolytic regulator of iron homeostasis. Haematologica 2009; 94: 840–849.
   PubMed Web of Science ®Google Scholar
• Brissot P, de Bels F. Current approaches to the management of hemochromatosis. Hematology Am Soc Hematol Educ Program 2006; 2006: 36–41.
   Google Scholar
• Hoffbrand AV, Catovsky D, Tuddenham EG. Postgraduate haematology. 5th ed. Malden, MA: Blackwell Pub, 2005.
   Google Scholar
• Gibert Y, Lattanzi Vi, Fraenkel PG. Knockdown of matriptase-2 increases hepcidin expression in a BMP-dependent manner in zebrafish embryos. ASH Annu Meet Abstr 2009; 114: 4050.
   Google Scholar
• Létocart E, Le Gac G, Majore S et al. A novel missense mutation in SLC40A1 results in resistance to hepcidin and confirms the existence of two ferroportin-associated iron overload diseases. Br J Haematol 2009; 147: 379–385.
   PubMed Web of Science ®Google Scholar
• Lee MT, Piomelli S, Granger S et al. Stroke prevention trial in sickle cell anemia (STOP): extended follow-up and final results. Blood 2006; 108: 847–852.
   PubMed Web of Science ®Google Scholar
• Telfer PT, Prestcott E, Holden S et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 2000; 110: 971–977.
   PubMed Web of Science ®Google Scholar
• Kirk P, Roughton M, Porter JB et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009; 120: 1961–1968.
   PubMed Web of Science ®Google Scholar
• Anderson Li, Holden S, Davis B et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22: 2171–2179.
   PubMed Web of Science ®Google Scholar
• Pootrakul P, Breuer W, Sametband M et al. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator. Blood 2004; 104: 1504–1510.
   PubMed Web of Science ®Google Scholar
• Koren A, Fink D, Admoni O, Tennenbaum-Rakover Y, Levin C. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients. Eur J Haematol 2010; 84: 72–78.
   PubMed Web of Science ®Google Scholar
• Zanninelli G, Breuer W, Cabantchik ZJ. Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients. Br J Haematol 2009; 147: 744–751.
   PubMed Web of Science ®Google Scholar
• Piga A, Longo F, Duca L et al. High nontransferrin bound iron levels and heart disease in thalassemia major. Am J Hematol 2009; 84: 29–33.
   PubMed Web of Science ®Google Scholar
• Taher A, Musallam KM, El Rassi F et al. Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia. Br J Haematol 2009; 146: 569–572.
   PubMed Web of Science ®Google Scholar
• Anderson GJ. Mechanisms of iron loading and toxicity. Am J Hematol 2007; 82 (12 Suppl.): 1128–1131.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, de Stefano P et al. Survival and complications in thalassemia. Ann NY Acad Sci 2005; 1054: 40–47.
   PubMed Web of Science ®Google Scholar
• Oudit GY, Sun H, Trivieri MG et al. L-type Ca2± channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med 2003; 9: 1187–1194.
   PubMed Web of Science ®Google Scholar
• Wood JC, Claster S, Carson S et al. Vitamin D deficiency, cardiac iron and cardiac function in thalassaemia major. Br J Haematol 2008; 141: 891–894.
   PubMed Web of Science ®Google Scholar
• Noetzli Li, Papudesi J, Coates TD et al. Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood 2009; 114: 4021–4026.
   PubMed Web of Science ®Google Scholar
• de Assis RA, Andreza AFP, Alexandre HC et al. Non-invasive assessment of pancreatic iron stores by magnetic resonance imaging (MRI) in beta-thalassemic patients. ASH Annu Meet Abstr 2009; 114: 4052.
   Google Scholar
• Maggio A. Light and shadows in the iron chelation treatment of haematological diseases. Br J Haematol 2007; 138: 407–421.
   PubMed Web of Science ®Google Scholar
• Porter JB. Concepts and goals in the management of transfusional iron overload. Am J Hematol 2007; 82 (12 Suppl.): 1136–1139.
   PubMed Web of Science ®Google Scholar
• Delea TE, Edelsberg J, Sofrygin O et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion 2007; 47: 1919–1929.
   PubMed Web of Science ®Google Scholar
• Porter JB, Jaswon MS, Huehns ER et al. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J Haematol 1989; 73: 403–409.
   PubMed Web of Science ®Google Scholar
• Singer ST, Vichinsky EP. Deferoxamine treatment during preg-nancy: is it harmful? Am J Hematol 1999; 60: 24–26.
   PubMed Web of Science ®Google Scholar
• Porter JB, Abeysinghe RD, Marshall L et al. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood 1996; 88: 705–713.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Piga A. Current status in iron chelation in hemoglobinopathies. Curr Mol Med 2008; 8: 663–674.
   PubMed Web of Science ®Google Scholar
• Roberts D, Brunskill S, Doree C, Williams S, Howard J, Hyde C. Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database Syst Rev 2007; (3): CD004839.
   Google Scholar
• Cohen AR, Galanello R, Piga A et al. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol 2000; 108: 305–312.
   PubMed Web of Science ®Google Scholar
• Cohen AR, Galanello R, Piga A et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003; 102: 1583–1587.
   PubMed Web of Science ®Google Scholar
• Ceci A, Baiardi P, Felisi M et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002; 118: 330–336.
   PubMed Web of Science ®Google Scholar
• Mamtani M, Kulkarni H. Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: a systematic review and meta-analysis. Br J Haematol 2008; 141: 882–890.
   PubMed Web of Science ®Google Scholar
• Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 2006; 107: 3436–3441.
   PubMed Web of Science ®Google Scholar
• Berdoukas V, Chouliaras G, Moraitis P, Zannikos K, Berdoussi E, Ladis V. The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study. J Cardiovasc Magn Reson 2009; 11: 20.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Cappellini MD, de Stefano P et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006; 107: 3733–3737.
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Berdoukas V, Karagiorga M et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107: 3738–3744.
   PubMed Web of Science ®Google Scholar
• Piga A, Gaglioti C, Fogliacco E et al. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003; 88: 489–496.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Perrotta S, Agaoglu L et al. Efficacy and safety of deferasirox (Exjade®) in patients with beta-thalassemia major treated for up to 5 years. ASH Annu Meet Abstr 2009; 114: 4063.
   Google Scholar
• Daar S, Pathare A, Nick H et al. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia. Eur J Haematol 2009; 82: 454–457.
   PubMed Web of Science ®Google Scholar
• Vichinsky E. Clinical application of deferasirox: Practical patient management. Am J Hematol 2008; 83: 398–402.
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Porter JB, Cappellini MD et al. Efficacy and safety of deferasirox (Exjade®) in beta-thalassemia patients with myocardial siderosis: 2-year results from the EPIC cardiac sub-study. ASH Annu Meet Abstr 2009; 114: 4062.
   Google Scholar
• Smith G, Pennell DJ, Porter JB et al Improvement in right ventricularfunction following 1 year of deferasirox therapy in patients with beta-thalassemia. ASH Annu Meet Abstr 2009; 114: 5106.
   Google Scholar
• Taher A, El-Beshlawy A, Elalfy MS et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beat-thalassaemia: the ESCALATOR study. Eur J Haematol 2009; 82: 458–465.
   PubMed Web of Science ®Google Scholar
• Taher A, El-Beshlawy A, Elalfy MS et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol 2009; 147: 752–759.
   PubMed Web of Science ®Google Scholar
• Evans E, Kleinert, DA, Mennitt K et al. Iron chelation with deferasirox in thalassemia major patients with low iron burdens and moderate to high transfusion regimens. ASH Annu Meet Abstr 2009; 114: 4070.
   Google Scholar
• Chirnomas D, Smith AL, Braunstein J et al. Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood 2009; 114: 4009–4013.
   PubMed Web of Science ®Google Scholar
• Garbowski MW, Fabre M, Evans P, Porter JB. Vitamin C status in transfusionally iron-overloaded patients on long-term deferasirox and its relationship to myocardial iron removal. ASH Annu Meet Abstr 2009; 114: 2005.
   Google Scholar
• Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998; 103: 361–364.
   PubMed Web of Science ®Google Scholar
• Mourad FH, Hoffbrand AV, Sheikh-Taha M et al. Comparison between desferrioxamine and combined therapy with desferriox-amine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol 2003; 121: 187–189.
   PubMed Web of Science ®Google Scholar
• Tanner MA, Galanello R, Dessi C et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007; 115: 1876–1884.
   PubMed Web of Science ®Google Scholar
• Maggio, Vitrano A, Capra M et al. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassae-mia major patients: a randomized clinical trial. Br J Haematology 2009; 145: 245–254.
   PubMed Web of Science ®Google Scholar
• Telfer PT, Warburton F, Christou S et al. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone. Haematologica 2009; 94: 1777–1778.
   PubMed Web of Science ®Google Scholar
• Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 2010; 148: 466–475.
   PubMed Web of Science ®Google Scholar
• Lal A, Sweeters N, Herz M et al. Safety of combined chelation therapy with deferasirox and deferoxamine in transfusion-depen-dent thalassemia. ASH Annu Meet Abstr 2009; 114: 2021.
   Google Scholar
• Nemeth E. Development of hepcidin agonists and antagonists. ASH Annu Meet Abstr 2009; 114: SCI–27.
   Google Scholar